Trial Profile
Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2019
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Lenvatinib (Primary) ; Sorafenib (Primary) ; Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- 22 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2018 New trial record